Study-related adverse events The adverse events most commonly reported in 5% of adult patients treated with Victoza 1.8 mg vs Januvia 100 mg, both in combination with metformin, were nausea (21.8% vs 7.8%), diarrhea (16.3% vs 9.3%), decreased appetite (8.9% vs 3.4%), vomiting (7.4% vs 4.9%), headache (6.4% vs 5.9%), nasopharyngitis (5.9% vs 3.4%), and increased lipase (5.5% vs 4.4%)
2 Until CagriSema reaches the UK, Mounjaro and Wegovy remain the licensed options for adults with both type 2 diabetes and obesity who want a GLP-1 drug for weight management
2023 NEJM, 20% MACE reduction)
A Medicare beneficiary who qualifies for coverage under the expanded criteria or the Part D phase-in plan will pay only $50 a month for a covered GLP-1 medication
Research has focused on its regenerative effects across multiple tissue types tendons, ligaments, muscle, joint cartilage, and gut lining making it one of the most clinically interesting recovery peptides available